Literature DB >> 26487274

Clarification of the definition of complete response in multiple myeloma.

B G M Durie1, J F S Miguel2, J Blade3, S V Rajkumar4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26487274     DOI: 10.1038/leu.2015.290

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

2.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

  2 in total
  10 in total

1.  Innovations in treatment and response evaluation in multiple myeloma.

Authors:  Ruth Wester; Pieter Sonneveld
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

2.  How I treat a refractory myeloma patient who is not eligible for a clinical trial.

Authors:  Siyang Leng; Divaya Bhutani; Suzanne Lentzsch
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Authors:  Torben Plesner; Hendrik-Tobias Arkenau; Peter Gimsing; Jakub Krejcik; Charlotte Lemech; Monique C Minnema; Ulrik Lassen; Jacob P Laubach; Antonio Palumbo; Steen Lisby; Linda Basse; Jianping Wang; A Kate Sasser; Mary E Guckert; Carla de Boer; Nushmia Z Khokhar; Howard Yeh; Pamela L Clemens; Tahamtan Ahmadi; Henk M Lokhorst; Paul G Richardson
Journal:  Blood       Date:  2016-08-16       Impact factor: 22.113

4.  Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Authors:  Kazunori Murata; Samuel I McCash; Brittany Carroll; Alexander M Lesokhin; Hani Hassoun; Nikoletta Lendvai; Neha S Korde; Sham Mailankody; Heather J Landau; Guenther Koehne; David J Chung; Sergio A Giralt; Lakshmi V Ramanathan; Ola Landgren
Journal:  Clin Biochem       Date:  2016-09-21       Impact factor: 3.281

Review 5.  Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Authors:  Philippe Moreau; Niels W C J van de Donk; Jesus San Miguel; Henk Lokhorst; Hareth Nahi; Dina Ben-Yehuda; Michele Cavo; Gordon Cook; Michel Delforge; Hermann Einsele; Sonja Zweegman; Heinz Ludwig; Christoph Driessen; Antonio Palumbo; Thierry Facon; Torben Plesner; Meletios Dimopoulos; Pia Sondergeld; Pieter Sonneveld; María-Victoria Mateos
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

6.  Survival analysis of multiple myeloma patients after autologous stem cell transplantation.

Authors:  Ju Li; Yan Zhu
Journal:  Stem Cell Investig       Date:  2019-12-12

7.  Immunotyping Provides Equivalent Results to Immunofixation in a Population with a High Prevalence of Monoclonal Gammopathies.

Authors:  Katie L Thoren; Samuel I McCash; Kazunori Murata
Journal:  J Appl Lab Med       Date:  2021-11-01

Review 8.  New developments in the treatment of multiple myeloma - clinical utility of daratumumab.

Authors:  Cian McEllistrim; Janusz Krawczyk; Michael E O'Dwyer
Journal:  Biologics       Date:  2017-04-11

9.  Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Authors:  Meletios A Dimopoulos; Jesus San-Miguel; Andrew Belch; Darrell White; Lotfi Benboubker; Gordon Cook; Merav Leiba; James Morton; P Joy Ho; Kihyun Kim; Naoki Takezako; Philippe Moreau; Jonathan L Kaufman; Heather J Sutherland; Marc Lalancette; Hila Magen; Shinsuke Iida; Jin Seok Kim; H Miles Prince; Tara Cochrane; Albert Oriol; Nizar J Bahlis; Ajai Chari; Lisa O'Rourke; Kaida Wu; Jordan M Schecter; Tineke Casneuf; Christopher Chiu; David Soong; A Kate Sasser; Nushmia Z Khokhar; Hervé Avet-Loiseau; Saad Z Usmani
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

10.  Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.

Authors:  Suzette Girgis; Shun Xin Wang Lin; Kodandaram Pillarisetti; Arnob Banerjee; Tara Stephenson; Xuewen Ma; Shoba Shetty; Tong-Yuan Yang; Brandi W Hilder; Qun Jiao; Brett Hanna; Homer C Adams; Yu-Nien Sun; Amarnath Sharma; Jennifer Smit; Jeffrey R Infante; Jenna D Goldberg; Yusri Elsayed
Journal:  Target Oncol       Date:  2022-06-24       Impact factor: 4.864

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.